A Brazilian company has begun test production of the active ingredient for Russia's Sputnik V vaccine for COVID-19 and plans to reach full manufacturing in April, as reported Financial Post on Thursday.
"This week we started making a pilot lot of the active ingredient for learning purposes, not for use," said Miguel Giudicissi, chief science officer at União Quimica.
Giudicissi said União Quimica's contract with the Russian Direct Investment Fund (RDIF), which is marketing the vaccine, provides for a 100% transfer of technology, adding that "this will give Brazil autonomy in COVID-19 vaccine supplies."
The partners will provide additional Phase III clinical trial data involving 22,000 participants in Russia from the 44,000-subject programme that should convince Anvisa that Sputnik V is safe and has an efficacy of 90%, Giudicissi added.
To read more NewsPoints articles, click here.